Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.
This review shall present an update in anticancer ganglioside-based immunotherapies, with particular emphasis on molecular vaccines and anti-idiotype mAbs produced by the Center of Molecular Immunology (Havana, Cuba). The project comprises vaccines of N-acetyl or N-glycolylneuraminic acid GM3 ganglioside incorporated into very small proteoliposomes and anti-idiotype antibodies to glycolylated gangliosides. Development of these vaccine preparations from preclinical models of melanoma, breast and lung cancer to human investigation is summarized. A brief discussion on the progress and limitations of present-day clinical trials and future prospects is also included.
Fernández
Luis E
LE
Center of Molecular Immunology, PO Box 16040, Havana 11600, Cuba. luis@ict.cim.sld.cu
Alonso
Daniel F
DF
Gomez
Daniel E
DE
Vázquez
Ana M
AM
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014612:Vaccines / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D005732:Gangliosides; D014612:Vaccines